Burrows Scott L (CIK 1853327) reported 19 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Buy SYRE (7,500 shares), Sell SYRE (5,775 shares), Sell SYRE (1,725 shares), Buy SYRE (15,000 shares), Sell SYRE (5,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 5,775 | $505,601 |
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 1,725 | $152,438 |
| 2026-06-26 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 15,000 | $217,500 |
| 2026-06-26 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 5,000 | $435,600 |
| 2026-06-26 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 10,000 | $871,400 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 1,801 | $125,620 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 2,599 | $183,931 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 3,100 | $223,386 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 12,500 | $181,250 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 12,500 | $892,125 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 7,500 | $108,750 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 6,200 | $305,102 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 1,300 | $64,974 |
| 2026-03-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Buy | 2,500 | $36,250 |
| 2026-03-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 2,300 | $93,288 |
| 2026-03-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 200 | $8,332 |
| 2025-09-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sell | 18,428 | $299,639 |
Source: SEC Form 4 filings · as of 2026-07-02